Related Experiment Video

Updated: Jun 5, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.5K

Extracellular vesicles-based vaccines: Emerging immunotherapies against cancer

Yuhua Meng1, Zhimeng Yao2, Xiurong Ke3

  • 1Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China; State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, China.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|December 12, 2024
PubMed

Insights

Extracellular vesicle (EV) vaccines show promise for cancer immunotherapy, overcoming limitations of traditional cell-based vaccines. These novel EV vaccines offer improved targeting, immune response, and safety for treating solid tumors.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Cancer vaccines aim to boost T-cell immunity against solid tumors, often combined with other therapies.
  • Traditional tumor cell-based vaccines face challenges like poor immunogenicity and delivery issues.
  • Extracellular vesicles (EVs) are emerging as superior platforms for drug delivery and vaccines.

Purpose of the Study:

  • To review current research on extracellular vesicle (EV) vaccines for cancer immunotherapy.
  • To highlight the advantages of EV vaccines over traditional cell-based vaccines.
  • To discuss novel neoantigens for developing effective EV cancer vaccines.

Main Methods:

  • Literature review of recent findings on EV vaccines in cancer research.
  • Comparative analysis of EV vaccines versus cell-based vaccines.
  • Exploration of EV properties for targeted delivery and immune response modulation.

Main Results:

  • EVs offer organ-specific targeting, enhanced immune responses, and superior tissue delivery.
  • EV vaccines demonstrate higher safety, easier preservation, and transport compared to cell-based vaccines.
  • EVs can overcome challenges associated with tumor heterogeneity and the tumor immune microenvironment.

Conclusions:

  • EV vaccines represent a significant advancement in cancer immunotherapy.
  • EVs provide a versatile and effective platform for developing next-generation cancer vaccines.
  • Further research into novel neoantigens will enhance the efficacy of EV-based cancer therapies.
Keywords:
CancerExtracellular vesiclesImmunotherapiesNeoantigensTumor antigenVaccine carrierVaccines

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

634

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
338
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K